All In Biotech

Drug Trial Radar · NCT07326813

A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis

A Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 477 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

477

Planned (sponsor's estimate)

Start

Jan 12, 2026

Primary completion

Jul 12, 2027

Study completion Dec 3, 2027

Sponsor

Lead sponsor
InventisBio Co., LtdIndustry
Sponsor type
Industry
First posted
Jan 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis. Safety and efficacy assessments will be conducted during the scheduled study visits throughout the trial. After completing the respective treatment, all subjects will undergo a safety follow-up. Both the investigators and subjects will remain blinded throughout the entire treatment period. During the study, subjects are required to provide blood samples for pharmacokinetic (PK) and pharmacodynamic (PD) analyses at the time points specified in the trial protocol.

Conditions

  • Plaque Psoriasis

Interventions

  • D-2570 TabletDrug

    D-2570 is a novel inhibitor targeting the TYK2 pseudokinase domain

  • BMS-986165 TabletDrug

    BMS-986165 is a novel inhibitor targeting TYK2

  • PlaceboDrug

    A placebo refers to a tablet that has no therapeutic effect on medication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of different doses of D-2570 compared with placebo in the treatment of patients with moderate to severe plaque psoriasisTime frame: Treatment for 16 weeks after enrollment
  2. To evaluate the efficacy of different doses of D-2570 compared with placebo in the treatment of patients with moderate to severe plaque psoriasisTime frame: Treatment for 16 weeks after enrollment
  3. To evaluate the efficacy of different doses of D-2570 compared with placebo in the treatment of patients with moderate to severe plaque psoriasisTime frame: Treatment for 16 weeks after enrollment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Skin Disease Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.